An observational study in Inflammatory Bowel Diseases, Crohn Disease and Ulcerative Colitis, sponsored by Assiut University. Not yet recruiting. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Assiut University · Observational
Among 45 studies in Inflammatory Bowel Diseases by Assiut University — 20 open to participants now, 20 under way, none of them phase 3. Inflammatory Bowel Diseases · Assiut University.
Among the 45 studies in Inflammatory Bowel Diseases by Assiut University, this one is the 13th largest by planned enrollment of the 41 observational ones that give a count, is one of 12 that started in 2026, is one of 41 observational ones, reaches primary completion later than 11 of the 19 other live ones, and was the 42nd registered.
1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →20 of the 45 studies in Inflammatory Bowel Diseases by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University · Sites in Egypt
Ages up to 18
Assiut University
Ages 18+
Assiut University · Sites in Egypt
Ages 18–65
Assiut University
Ages 18+
Assiut University
Ages up to 17
By country, each count listing its studies:
Of the 277 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 117 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.
This study: Up to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 12 started in 2026.
This study's planned enrollment of 100 is below the median of 140 across 626 observational studies indexed under Inflammatory Bowel Diseases.
Median enrollment 65 across the 4 interventional studies, 100 across the 41 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,079 studies on the registry; 2,177 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
11 of the studies in Inflammatory Bowel Diseases by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07259603Assiut UniversityAssociation Between Vitamin D Deficiency and Inflammatory Bowel Disease | 2027-01 |
| NCT07637045Assiut UniversityUrinary PGE-MUM as a Marker for Ulcerative Colitis Activity | 2027-01-31 |
| NCT07343726Assiut UniversityImpact of Obesity on Response to Therapy and Clinical Outcom in Patients With Inflammatory Bowel Disease | 2027-02 |
| NCT07387588Assiut UniversityAnemia as Predictor of Outcome in IBD Pateints in Assuit University Hospitals | 2027-03 |
| NCT05002166Assiut UniversityClinical Characteristics and Risk Factors of Children Suffering From Inflammatory Bowel Diseases At Assiut University Children Hospital | 2027-07-20 |
Add all 11 to your calendar (.ics) → With an account.
Among the 45 studies in Inflammatory Bowel Diseases by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This combined retrospective-prospective cohort study aims to evaluate the effectiveness, safety, and adverse events of conventional versus biologic therapy in children and adolescents with inflammatory bowel disease at Assiut University Children Hospital.
Pediatric-onset inflammatory bowel disease differs from adult-onset disease in phenotype, disease extent, and long-term prognosis. Conventional therapy (5-aminosalicylates, corticosteroids, and immunomodulators) and biologic therapy (mainly anti-TNFα agents) are used for induction and maintenance of remission.
This observational cohort study will include pediatric patients with confirmed Crohn's disease, ulcerative colitis, or IBD-unclassified. Patients will be classified into conventional therapy and biologic therapy groups. Clinical remission, response rates, steroid-free remission, adverse events, and growth parameters will be assessed over a 12-month period.
Children and adolescents up to 18 years of age with confirmed inflammatory bowel disease receiving conventional and/or biologic therapy at Assiut University Children Hospital and the Health Insurance IBD Committee, Assiut Branch.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients managed with 5-aminosalicylates, corticosteroids, and/or immunomodulators without biologic exposure during the observation period.
Patients who received biologic therapy (with or without concomitant conventional agents) during the observation period.
Clinical remission rate
Proportion of patients achieving clinical remission at week 8-12, 6 months, and 12 months, defined as PCDAI ≤ 10 for Crohn's disease or PUCAI \< 10 for ulcerative colitis.
Time frame: At week 8-12, 6 months, and 12 months
Clinical response rate
Proportion of patients achieving clinical response, defined as a decrease from baseline of ≥12.5 points in PCDAI (Crohn's disease) or ≥20 points in PUCAI (ulcerative colitis).
Time frame: At week 8-12, 6 months, and 12 months
Steroid-free remission rate
Proportion of patients in clinical remission without systemic corticosteroid use.
Time frame: At 12 months
Incidence of adverse events
Proportion of patients experiencing adverse events (infusion/injection reactions, infections, hematologic abnormalities, hepatotoxicity), graded according to CTCAE-adapted criteria
Time frame: Through 12 months
Change in growth parameters
Change in height z-score, weight z-score, and BMI z-score from baseline.
Time frame: From baseline to 12 months
Treatment escalation or switch rate
Proportion of patients requiring treatment escalation or switching between conventional and biologic agents.
Time frame: Through 12 months
No study locations are listed for this record.
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
Of 243 non-industry observational studies under Inflammatory Bowel Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 132. This study's planned 12 months is below that.
Counting every sponsor, half of 280 studies reached it within 36 months; a quarter within 20 and three quarters within 122.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.